Bryan Morton founded EUSA Pharma, Inc in 2006. A transatlantic specialty pharmaceutical company focused on oncology and critical care. Bryan was the President and CEO of EUSA until the sale of the company to Jazz Pharmaceuticals for a total consideration of $700m in 2012. In March 2015 Bryan, together with Essex Woodlands reacquired certain EUSA assets from Jazz Pharmaceuticals in order to create a new specialty Pharma company, trading once again as EUSA Pharma. Prior to founding the original EUSA Pharma Bryan was the CEO of Zeneus Pharma, which he founded following the $120m acquisition of Elan’s European business. Zeneus was subsequently acquired by Cephalon in late 2005 for $360m after two highly successful years of rapid growth and profitable trading.

Bryan’s entrepreneurial success is built on 30 years of commercial business development and general management experience in the pharmaceutical industry, spent largely with Merck & Co Inc. and Bristol Myers Squibb. He has extensive international experience, particularly in the US and Europe, having held senior positions, including at Board and SVP level, in America, the UK, Belgium and Australia. Bryan is Executive Chairman of EUSA Pharma, Chairman of VHsquared and is also a Non-Executive Director on the Oxtex Board.

Bryan holds an MBA from Durham University and is an Honorary Professor at Durham University Business School. Bryan also holds a BSc in Pharmacology from Aberdeen University in Scotland and is a graduate of the INSEAD European Management Programme.

In 2016 Bryan was honored by Her Majesty the Queen and was awarded a CBE (Commander of the Most Excellent Order of the British Empire) for services to the Healthcare Industry.